Loss of thalamic intralaminar nuclei in progressive supranuclear palsy and Parkinson's disease: Clinical and therapeutic implications

Brain

Volumn 123, Issue 7, 2000, Pages 1410-1421

  Henderson, J M ^a   Carpenter, K ^a   Cartwright, H ^a   Halliday, G M ^a  

^a NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

Author keywords

Caudal intralaminar thalamic nuclei; Limbic thalamic nuclei; Parkinson's disease; Progressive supranuclear palsy

Indexed keywords

ARTICLE; BASAL GANGLION; CAUDATE NUCLEUS; CELL DENSITY; CELL LOSS; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; HUMAN; HUMAN TISSUE; LEWY BODY; LIMBIC SYSTEM; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; PARKINSON DISEASE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; THALAMUS INTRALAMINAR NUCLEUS; THALAMUS NUCLEUS;

EID: 0033918014     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/123.7.1410     Document Type: Article

References (50)

1. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. [Review]. Acta Neuropathol (Berl) 1991; 82: 239-59.
2. Braak H, Braak E. Evolution of neuronal changes in the course of Alzheimer's disease. [Review]. J Neural Transm 1998; 53: 127-40.
3. Braak H, Braak E, Yilmazer D, de Vos RA, Jansen EN, Bohl J. Pattern of brain destruction in Parkinson's and Alzheimer's diseases. [Review]. J Neural Transm 1996; 103: 455-90.
4. Cullen KM. A novel nickel avidin-biotin-peroxidase method for histochemical visualization of neurofibrillary tangles, senile plaques, and neuropil threads. J Histochem Cytochem 1994; 42: 1383-91.
5. Daniel SE. Parkinson's disease. In: Cruz-Sánchez FF, Ravid R, Cuzner ML, editors. Neuropathological diagnostic criteria for brain banking. Amsterdam: IOS Press; 1995. p. 72-9.
6. Daniel SE, de Bruin VM, Lees AJ. The clinical and pathological spectrum of Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy): a reappraisal. [Review]. Brain 1995; 118: 759-70.
7. Engelborghs S, Marien P, Marten JJ, De Deyn PP. Functional anatomy, vascularisation and pathology of the human thalamus. Acta Neurol Belg 1998; 98: 252-65.
8. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991; 114: 2283-301.
9. Fearnley J, Lees A. Pathology of Parkinson's disease. [Review]. In: Calne DB, editor. Neurodegenerative diseases. Philadelphia: W.B. Saunders; 1994. p. 545-54.
10. Forno LS. Neuropathology of Parkinson's disease. [Review]. J Neuropathol Exp Neurol 1996; 55: 259-72.
11. Gai WP, Halliday GM, Blumbergs PC, Geffen LB, Blessing WW. Substance P-containing neurons in the mesopontine tegmentum are severely affected in Parkinson's disease. Brain 1991; 114: 2253-67.
12. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson's disease. [Review]. Arch Neurol 1999; 56: 33-9.
13. Groenewegen HJ, Berendse HW. The specificity of the 'nonspecific' midline and intralaminar thalamic nuclei. Trends Neurosci 1994; 17: 52-7.
14. Hallanger AE, Levey AI, Lee HJ, Rye DB, Wainer BH. The origins of cholinergic and other subcortical afferents to the thalamus in the rat. J Comp Neurol 1987; 262: 105-24.
15. Halliday GM, McRitchie DA, Cartwright HR, Pamphlett RS, Hely MA, Morris JGL. Midbrain neuropathology in idiopathic Parkinson's disease and diffuse Lewy body disease. J Clin Neurosci 1996; 3: 52-60.
16. Harding AJ, Halliday GM. Simplified neuropathological diagnosis of dementia with Lewy bodies. Neuropathol Appl Neurobiol 1998; 24: 195-201.
17. Harding AJ, Halliday GM, Cullen K. Practical considerations for the use of the optical disector in estimating neuronal number. J Neurosci Methods 1994; 51: 83-9.
18. Hardman CD, Halliday GM. The external globus pallidus in patients with Parkinson's disease and progressive supranuclear palsy. Mov Disord 1999a; 14: 626-33.
19. Hardman CD, Halliday GM. The internal globus pallidus is affected in progressive supranuclear palsy and Parkinson's disease. Exp Neurol 1999b; 158: 135-42.
20. Hardman CD, McRitchie DA, Halliday GM, Cartwright HR, Morris JG. Substantia nigra pars reticulata in Parkinson's disease. Neurodegeneration 1996; 5: 49-55.
21. Hardman CD, Halliday GM, McRitchie DA, Cartwright HR, Morris JG. Progressive supranuclear palsy affects both the substantia nigra pars compacta and reticulata. Exp Neurol 1997a; 144: 183-92.
22. Hardman CD, Halliday GM, McRitchie DA, Morris JG. The subthalamic nucleus in Parkinson's disease and progressive supranuclear palsy. J Neuropathol Exp Neurol 1997b; 56: 132-42.
23. Hauw JJ, Daniel SE, Dickson D, Horoupian DS, Jellinger K, Lantos PL, et al. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). [Review]. Neurology 1994; 44: 2015-9.
24. Henderson JM, Carpenter K, Cartwright H, Halliday GM. Degeneration of the centre median-parafascicular complex in Parkinson's disease. Ann Neurol 2000; 47: 345-52.
25. Hirai T, Jones EG. A new parcellation of the human thalamus on the basis of histochemical staining. Brain Res Brain Res Rev 1989; 14: 1-34.
26. Hirsch EC, Graybiel AM, Duyckaerts C, Javoy-Agid F. Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson disease and in progressive supranuclear palsy. Proc Natl Acad Sci USA 1987; 84: 5976-80.
27. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427-42.
28. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry 1982; 140: 566-72.
29. Jellinger K. The pedunculopontine nucleus in Parkinson's disease, progressive supranuclear palsy and Alzheimer's disease. J Neurol Neurosurg Psychiatry 1988; 51: 540-3.
30. Lantos PL. The neuropathology of progressive supranuclear palsy. [Review]. J Neural Transm 1994; Suppl 42: 137-52.
31. Litvan I. Progressive supranuclear palsy revisited. [Review]. Acta Neurol Scand 1998; 98: 73-84.
32. Litvan I, Campbell G, Mangone CA, Verny M, McKee A, Chaudhuri KR, et al. Which clinical features differentiate progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) from related disorders? A clinicopathological study. Brain 1997; 120: 65-74.
33. Lozano AM, Lang AE, Hutchison WD, Dostrovsky JO. New developments in understanding the etiology of Parkinson's disease and in its treatment. [Review]. Curr Opin Neurobiol 1998; 8: 783-90.
34. Matsumoto R, Nakano I, Arai N, Suda M, Oda M. Progressive supranuclear palsy with asymmetric lesions in the thalamus and cerebellum, with special reference to the unilateral predominance of many torpedoes. Acta Neuropathol (Berl) 1996; 92: 640-4.
35. 18F]dopa PET. J Neurol Neurosurg Psychiatry 1998; 64: 314-9.
36. Münkle MC, Waldvogel HJ, Faull RL. Calcium-binding protein immunoreactivity delineates the intralaminar nuclei of the thalamus in the human brain. Neuroscience 1999; 90: 485-91.
37. Nakano K, Hasegawa Y, Tokushige A, Nakagawa S, Kayahara T, Mizuno N. Topographical projections from the thalamus, subthalamic nucleus and pedunculopontine tegmental nucleus to the striatum in the Japanese monkey, Macaca fuscata. Brain Res 1990; 537: 54-68.
38. Nauta WJH, Mehler WR. Projections of the lentiform nuclei in the monkey. Brain Res 1966; 1: 3-42.
39. Oakman SA, Fans PL, Kerr PE, Cozzari C, Hartman BK. Distribution of pontomesencephalic cholinergic neurons projecting to substantia nigra differs significantly from those projecting to ventral tegmental area. J Neurosci 1995; 15: 5859-69.
40. Parent A. Extrinsic connections of the basal ganglia. [Review]. Trends Neurosci 1990; 13: 254-8.
41. Pasquier F, Delacourte A. Non-Alzheimer degenerative dementias. [Review]. Curr Opin Neurol 1998; 11: 417-27.
42. Percheron G, François C, Yelnik J, Fénelon G, Talbi B. The basal ganglia related system of primates: definition, description and informational analysis. In: Percheron G, McKenzie JS, Féger J, editors. The basal ganglia IV. New York: Plenum Press; 1994. p. 3-20.
43. Sadikot A, Parent A, Francois C. Efferent connections of the centromedian and parafascicular thalamic nuclei in the squirrel monkey: a PHA-L study of subcortical projections. J Comp Neurol 1992; 315: 137-59.
44. Sergeant N, Wattez A, Delacourte A. Neurofibrillary degeneration in progressive supranuclear palsy and corticobasal degeneration: tau pathologies with exclusively 'exon 10' isoforms. J Neurochem 1999; 72: 1243-9.
45. Sidibé M, Smith Y. Differential synaptic innervation of striatofugal neurones projecting to the internal or external segments of the globus pallidus by thalamic afferents in the squirrel monkey. J Comp Neurol 1996; 365: 445-65.
46. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies [letter]. Nature 1997; 388: 839-40.
47. Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy: a heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 1964; 10: 333-59.
48. Takeda A, Hashimoto M, Mallory M, Sundsumo M, Hansen L, Sisk A, et al. Abnormal distribution of the non-Aβ component of Alzheimer's disease amyloid precursor/α-synuclein in Lewy body disease as revealed by proteinase K and formic acid pretreatment. Lab Invest 1998; 78: 1169-77.
49. Xuereb JH, Perry EK, Candy JM, Bonham JR, Perry RH, Marshall E. Parameters of cholinergic neurotransmission in the thalamus in Parkinson's disease and Alzheimer's disease. J Neurol Sci 1990; 99: 185-97.
50. Xuereb JH, Perry RH, Candy JM, Perry EK, Marshall E, Bonham JR. Nerve cell loss in the thalamus in Alzheimer's disease and Parkinson's disease. Brain 1991; 114: 1363-79.